REGENERON PHARMACEUTICALS, INC. (REGN) — GTM Brief

GTM intelligence brief for REGENERON PHARMACEUTICALS, INC. (REGN). Business model, revenue motion, growth levers, management priorities, key risks, and operator-ready insights — sourced from public SEC filings and earnings material.

Report available · $29 one-time purchase · 30-day access

Report preview

Business Overview

Regeneron invents medicines for serious diseases like eye disorders, cancer, and allergic conditions, then sells them directly to patients through hospitals and pharmacies, and splits profits with large pharmaceutical partners like Sanofi and Bayer.

GTM Motion

Dupixent's global net product sales grew from 4.15 billion in FY2024 to 7.81 billion in FY2025, a 26% increase, and Regeneron's Q1 2026 Sanofi profit share jumped 42% year-over-year to .45 billion — new approvals in CSU, bullous pemphigoid, and pediatric asthma in multiple geographies expand the addressable patient base without requiring new drug development.

Revenue Structure

Net product sales — products Regeneron sells directly — totaled .53 billion in Q1 2026, led by EYLEA HD ($468M U.S.) and EYLEA ($473M U.S.), plus Libtayo globally ($438M).

Management Priorities

Regeneron is executing a dual-track strategy of defending and transitioning its ophthalmology franchise — notably the ongoing patient migration from EYLEA to EYLEA HD amid biosimilar pressure — while simultaneously scaling Dupixent across new indications and geographies as its primary growth engine.

Full report includes GTM Motion, Revenue Structure, Growth & Performance, Operator Intelligence, Talking Points, and Smart Questions — sourced from SEC filings.

Report sections

  • Business Overview — What the company does, how it makes money, and what's driving growth.
  • GTM Motion — Go-to-market model, channel mix, and revenue motion — directly disclosed or inferred from filings.
  • Revenue Structure & Product Portfolio — Products, segments, and key financial metrics from filings and official sources.
  • Growth & Performance — Key metrics with baselines, growth rates, drivers, and headwinds — from the source.
  • Management Narrative & Priorities — What leadership said publicly about demand, pipeline, pricing, and strategic bets.
  • Operator Intelligence — Role-specific takeaways for CRO, RevOps, Finance, and Customer Success.
  • Talking Points & Smart Questions — Built for interviews, account planning, customer calls, and business reviews.

Source-grounded labels

Every claim is labeled: Directly Disclosed (from SEC filings), Inferred from Disclosures, Not Disclosed, or Watch Items. No invented figures.